MCID: PYR010
MIFTS: 50

Peyronie's Disease

Categories: Reproductive diseases

Aliases & Classifications for Peyronie's Disease

MalaCards integrated aliases for Peyronie's Disease:

Name: Peyronie's Disease 40 12 15
Induratio Penis Plastica 12 32
Peyronie Disease 12 70
Balanitis Xerotica Obliterans 70
Peyronie's Fibromatosis 12
Peyronies Disease 40
Penile Induration 44

Classifications:



External Ids:

Disease Ontology 12 DOID:8616
ICD9CM 34 607.85
MeSH 44 D010411
NCIt 50 C3316
SNOMED-CT 67 155931002
ICD10 32 N48.6
UMLS 70 C0030848 C0152460

Summaries for Peyronie's Disease

MalaCards based summary : Peyronie's Disease, also known as induratio penis plastica, is related to peyronie disease and hypertrophic scars. An important gene associated with Peyronie's Disease is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Testosterone and Methyltestosterone have been mentioned in the context of this disorder. Affiliated tissues include prostate, heart and skin, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Peyronie's Disease

Diseases in the Peyronie Disease family:

Peyronie's Disease

Diseases related to Peyronie's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
# Related Disease Score Top Affiliating Genes
1 peyronie disease 32.4 TGFB1 IFNA2
2 hypertrophic scars 30.1 TGFB1 SMAD3
3 penile disease 29.6 TGFB1 IL6 IFNA2 IFNA1
4 proteasome-associated autoinflammatory syndrome 1 29.4 IL6 IFNA1 CCL2
5 pulmonary fibrosis 29.4 TGFB1 SMAD7 SMAD3 CCL2
6 ulcerative colitis 29.2 SMAD7 SMAD4 SMAD3 IL6
7 pulmonary fibrosis, idiopathic 28.0 TGFB3 TGFB2 TGFB1 SMAD7 SMAD4 SMAD3
8 impotence 11.1
9 sexual disorder 10.7
10 varicocele 10.4
11 cutaneous polyarteritis nodosa 10.4 SMAD3 IFNA2
12 vascular disease 10.3
13 fibromatosis 10.3
14 corneal intraepithelial neoplasm 10.3 IFNA2 IFNA1
15 fibrosis of extraocular muscles, congenital, 1 10.3
16 tricuspid valve prolapse 10.3 TGFB3 TGFB2
17 lymphomatoid granulomatosis 10.3 IFNA2 IFNA1
18 cryoglobulinemia, familial mixed 10.3 IFNA2 IFNA1
19 hypercholesterolemia, familial, 1 10.2
20 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
21 lipid metabolism disorder 10.2
22 plague 10.2
23 hydrocele 10.2
24 internal hordeolum 10.2 IFNA2 IFNA1
25 conjunctival squamous cell carcinoma 10.2 IFNA2 IFNA1
26 tracheal stenosis 10.2 TGFB3 TGFB1
27 prostatitis 10.2
28 tuberculoid leprosy 10.2 TGFB3 TGFB2 TGFB1
29 squamous papillomatosis 10.2 IFNA2 IFNA1
30 loeys-dietz syndrome 5 10.2 TGFB3 TGFB2 SMAD3
31 loeys-dietz syndrome 3 10.2 TGFB3 TGFB2 SMAD3
32 loeys-dietz syndrome 4 10.2 TGFB3 TGFB2 SMAD3
33 loeys-dietz syndrome 1 10.2 TGFB3 TGFB2 SMAD3
34 gorham's disease 10.2 IL6 IFNA2
35 scleroderma, familial progressive 10.2
36 premature ejaculation 10.2
37 hypogonadism 10.2
38 epithelioid sarcoma 10.2
39 47,xyy 10.2
40 cytokine deficiency 10.2
41 posterior urethral valves 10.2 TGFB1 IL6
42 discoid lupus erythematosus 10.1 IFNA2 IFNA1
43 autosomal dominant non-syndromic intellectual disability 19 10.1 SMAD4 SMAD3 HLA-A
44 albinism, ocular, with late-onset sensorineural deafness 10.1 SMAD4 SMAD3 HLA-A
45 null-cell leukemia 10.1 IL6 IFNA1
46 epidermoid cysts 10.1
47 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
48 urethritis 10.1
49 hyperuricemia 10.1
50 paresthesia 10.1

Comorbidity relations with Peyronie's Disease via Phenotypic Disease Network (PDN):


Bladder Neck Obstruction Prostatic Hypertrophy
Urethral Stricture

Graphical network of the top 20 diseases related to Peyronie's Disease:



Diseases related to Peyronie's Disease

Symptoms & Phenotypes for Peyronie's Disease

GenomeRNAi Phenotypes related to Peyronie's Disease according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 9.66 HLA-A
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 9.66 TGFB1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 9.66 HLA-A
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-115 9.66 IFNA1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.66 IFNA1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-140 9.66 TGFB1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-143 9.66 TGFB1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 9.66 HLA-A
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 9.66 HLA-A IFNA1 IFNA2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 9.66 HLA-A
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-195 9.66 IFNA1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.66 IFNA2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 9.66 IFNA1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 9.66 HLA-A
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.66 IFNA1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-56 9.66 TGFB1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.66 IFNA1
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 9.66 HLA-A
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 9.66 IFNA1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-88 9.66 IFNA1

MGI Mouse Phenotypes related to Peyronie's Disease:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.24 DCN IL6 MSTN PTN SMAD3 SMAD4
2 behavior/neurological MP:0005386 10.22 DCN HLA-A IL6 MSTN PTN SMAD3
3 cardiovascular system MP:0005385 10.16 IL6 MSTN SMAD3 SMAD4 SMAD7 TGFB1
4 digestive/alimentary MP:0005381 10.11 DCN IL6 MSTN SMAD3 SMAD4 SMAD7
5 homeostasis/metabolism MP:0005376 10.11 DCN IL6 MSTN PTN SMAD3 SMAD4
6 hematopoietic system MP:0005397 10.1 DCN HLA-A IL6 PTN SMAD3 SMAD4
7 immune system MP:0005387 10.1 CCL2 DCN HLA-A IL6 MSTN PTN
8 craniofacial MP:0005382 10.08 DCN MSTN SMAD3 SMAD4 SMAD7 TGFB1
9 endocrine/exocrine gland MP:0005379 10.03 DCN HLA-A IL6 SMAD3 SMAD4 SMAD7
10 mortality/aging MP:0010768 10 DCN HLA-A IL6 MSTN SMAD3 SMAD4
11 muscle MP:0005369 9.7 DCN IL6 MSTN SMAD4 SMAD7 TGFB1
12 renal/urinary system MP:0005367 9.5 DCN IL6 MSTN SMAD3 SMAD4 TGFB1
13 reproductive system MP:0005389 9.23 DCN IL6 PTN SMAD3 SMAD4 SMAD7

Drugs & Therapeutics for Peyronie's Disease

Drugs for Peyronie's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Testosterone Approved, Investigational Phase 4 58-22-0 6013
2
Methyltestosterone Approved Phase 4 58-18-4 6010
3
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
4
Testosterone enanthate Approved Phase 4 315-37-7 9416
5 Testosterone 17 beta-cypionate Phase 4
6
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
7 Neurotransmitter Agents Phase 2
8 abobotulinumtoxinA Phase 2
9 Cholinergic Agents Phase 2
10 Botulinum Toxins Phase 2
11 Botulinum Toxins, Type A Phase 2
12 Pharmaceutical Solutions Phase 2
13
Tocopherol Approved, Investigational Phase 1 1406-66-2
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
15
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
16
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
17 Tocotrienol Investigational Phase 1 6829-55-6
18 Nutrients Phase 1
19 Micronutrients Phase 1
20 Trace Elements Phase 1
21 Vitamin D2 Phase 1
22 Protective Agents Phase 1
23 Anabolic Agents Phase 1
24 Hormone Antagonists Phase 1
25 Hormones Phase 1
26 Vitamins Phase 1
27 Antineoplastic Agents, Hormonal Phase 1
28 Tocotrienols Phase 1
29 Tocopherols Phase 1
30 Antioxidants Phase 1
31 Ergocalciferols Phase 1
32 Androgens Phase 1
33 Calciferol Phase 1
34 Calcium, Dietary Phase 1
35
Calcium Nutraceutical Phase 1 7440-70-2 271
36
Triamcinolone Approved, Vet_approved 124-94-7 31307
37
Vitamin A Approved, Nutraceutical, Vet_approved 68-26-8, 11103-57-4 445354
38 retinol
39 Retinol palmitate
40 glucocorticoids
41 Anti-Inflammatory Agents
42 Triamcinolone diacetate
43 Triamcinolone hexacetonide
44 triamcinolone acetonide

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 A Phase 4, Single-Center, Multiple-Dose, Open-Label Trial to Evaluate the Efficacy of Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response After Prior Xiaflex® Treatment Unknown status NCT03767452 Phase 4 Xiaflex® 0.58 mg
2 Xiaflex® Plus Testosterone Treatment Pilot Study Protocol A Six-month, Pilot Project of Testosterone Treatment in Subjects Who Are Undergoing Xiaflex® Therapy for the Treatment of Peyronie's Disease Completed NCT03815331 Phase 4 Xiaflex®;Aveed
3 Comparison of Collagenase Clostridium Histolyticum to Surgery for the Management of Peyronie's Disease: A Randomized Trial Recruiting NCT04786106 Phase 4 Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH)
4 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01243411 Phase 3
5 A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for Up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01221623 Phase 3
6 A Phase 3, Double-blind, Randomized, Placebo-controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01221597 Phase 3
7 A Phase 3b, Open-label Pilot Study to Evaluate the Safety and Effectiveness of up to Four Treatment Cycles of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Men With Peyronie's Disease Completed NCT02267460 Phase 3
8 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
9 A Phase 2, Open-Label Study to Assess the Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Completed NCT01430169 Phase 2
10 The Efficacy of Botulinum Toxin Type a in Treating Peyronie's Disease Completed NCT00812838 Phase 2 100 units of Botulinum Toxin Type A;100 units Botulinum Toxin A
11 A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Two Times a Week for Up to Three Treatment Cycles (2 x 3) in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
12 A Randomized, Double-Blind, Placebo Controlled, Crossover Trial on Safety and Efficacy of Autologous Platelet-Rich Plasma for Treatment of Peyronie's Disease Recruiting NCT04512287 Phase 2 Autologous Platelet Rich Plasma
13 A Sequential, Randomized, Double-blind, Placebo-controlled, Prospective Study to Evaluate the Safety and Efficacy of the H-100 Treatment in Adult Male Volunteers With Peyronie's Disease Completed NCT02072018 Phase 1 H-100;Placebo
14 Evaluate the Safety and Feasibility of Injecting Placental Matrix-Derived Mesenchymal Stem Cells Into the Penis to Treat the Symptoms of Peyronie's Disease Completed NCT02395029 Phase 1
15 An Open-Label, Nine-Month Randomized Controlled Study of Testosterone (Testopel) Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Completed NCT01578473 Phase 1 Vitamin D2;Vitamin E;Testosterone Pellets
16 Treatment With Stromal Vascular Fraction of Peyronie´s Disease in Humans Not yet recruiting NCT04771442 Phase 1 Stromal vascular fraction
17 A Prospective Randomized Double Blinded Placebo Controlled Clinical Trial Evaluating the Combined Effect of Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) and Vacuum Erectile Device Combined With Manipulation Exercises on Peyronies Disease. Unknown status NCT03530540
18 The Role of Adipose Tissue Stem Cell Injection Through Corpora Cavernosa and Intra Dorsal Penile Artery in Management of Erectile Dysfunction Associated With Peyronie's Disease Unknown status NCT02414308 Adipose tissue stem cell injection
19 Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806 Completed NCT02298829 Subjects Previously Treated with AA4500
20 Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum (CCH or Xiapex®): Sexual and Psychological Impact and Results From 156 Patients' Questionnaires Data Completed NCT04370652
21 Does Size Matter: A Single Case Experimental Design of Limiting the Depth of Penetration During Intercourse Completed NCT04052217
22 Circumcision Versus Preputioplasty for BXO in Children: A Feasibility Randomised Controlled Trial Completed NCT02854995
23 Treatment Response to Xiaflex Based on Ultrasound Characterization of Plaque for Men With Peyronie's Disease Recruiting NCT03774264
24 Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease Recruiting NCT04821115
25 Fractionated Carbon Dioxide Laser Therapy for Treatment of Peyronie's Disease Not yet recruiting NCT04326465

Search NIH Clinical Center for Peyronie's Disease

Cochrane evidence based reviews: penile induration

Genetic Tests for Peyronie's Disease

Anatomical Context for Peyronie's Disease

MalaCards organs/tissues related to Peyronie's Disease:

40
Prostate, Heart, Skin, Testis, Neutrophil, Eye, Brain

Publications for Peyronie's Disease

Articles related to Peyronie's Disease:

(show top 50) (show all 2070)
# Title Authors PMID Year
1
Comparison of two different grafts for the surgical treatment of peyronie's disease. 61
33486807 2021
2
Comparison of Intralesional Hyaluronic Acid vs. Verapamil for the Treatment of Acute Phase Peyronie's Disease: A Prospective, Open-Label Non-Randomized Clinical Study. 61
32009312 2021
3
Peyronie's disease: pharmacological treatments and limitations. 61
33719851 2021
4
Predictors of Depression in Men With Peyronie's Disease Seeking Evaluation. 61
33712403 2021
5
Mental Disorders in Peyronie's Disease: A Swedish Cohort Study of 3.5 Million Men. 61
33081594 2021
6
Patient Attitudes Towards Surgical Management of Peyronie's Disease Prior to Men's Health Consultation. 61
33676956 2021
7
Medical, non-invasive, and minimally invasive treatment for Peyronie's disease: A systematic review. 61
33098745 2021
8
Buccal mucosa graft in surgical management of Peyronie's disease: Ultrasound features and clinical outcomes. 61
33754621 2021
9
Treatment Patterns and Healthcare Outcomes with Collagenase Clostridium Histolyticum vs Surgery in Peyronie's Disease: A Retrospective Claims Database Analysis. 61
33684795 2021
10
The evolution in the surgical management of Peyronie's disease. 61
33781136 2021
11
UK practice for penile prosthesis surgery: baseline analysis of the British Association of Urological Surgeons (BAUS) Penile Prosthesis Audit. 61
32869902 2021
12
Specific urogenital disease information-revealing male genital votive offerings dedicated to gods in ancient age sanctuary medicine. 61
33650539 2021
13
Non-invasive and surgical penile enhancement interventions for aesthetic or therapeutic purposes: a systematic review. 61
32575166 2021
14
Management of residual penile curvature after penile prosthesis placement. 61
33106463 2021
15
Peyronie's disease may negatively impact the sexual experience of a couple and female sexual function: a single center study. 61
33718058 2021
16
Vascular Necrosis of the Upper Extremity After Self-Treatment for Peyronie's Disease. 61
33307341 2021
17
Treatments of Peyronie's disease with Scutellaria baicalensis and surgery according to the disease course: a single-center retrospective study of 261 patients. 61
33615818 2021
18
Patients with Dupuytren's Contracture, Ledderhose Disease, and Peyronie's Disease are at higher risk of arthrofibrosis following total knee arthroplasty. 61
33640618 2021
19
3D-Printed Flexible Penile Model Simulator for Plaque Incision and Graft for Peyronie's Disease. 61
33588369 2021
20
Comparing and Contrasting Peyronie's Disease Guidelines: Points of Consensus and Deviation. 61
33423972 2021
21
The successful use of collagenase for Ledderhose disease (plantar fibromatosis) in a paediatric patient: a case report. 61
33708375 2021
22
A Preliminary Report on Quality of Life and Sexual Function in Brain Tumor Patients. 61
33563548 2021
23
Long-acting liposomal bupivacaine and postoperative opioid use after Peyronie's disease surgery: a pilot study. 61
33532307 2021
24
Surgical outcomes after collagenase Clostridium histolyticum failure in patients with Peyronie's disease in a multicenter clinical study. 61
33420247 2021
25
Review of the Current Status of Low Intensity Extracorporeal Shockwave Therapy (Li-ESWT) in Erectile Dysfunction (ED), Peyronie's Disease (PD), and Sexual Rehabilitation After Radical Prostatectomy With Special Focus on Technical Aspects of the Different Marketed ESWT Devices Including Personal Experiences in 350 Patients. 61
32499189 2021
26
The use of collagen fleece (TachoSil) as grafting material in the surgical treatment of Peyronie's disease. A comprehensive narrative review. 61
33452519 2021
27
Long-term outcomes after plaque incision and grafting for Peyronie's disease: comparison of porcine dermal and bovine pericardium grafts. 61
32981219 2021
28
Defining the impact of Peyronie's disease on the psychosocial status of gay men. 61
32909401 2021
29
Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature. 61
33420664 2021
30
Funding Peyronie's disease: funding sources for primary research literature. 61
32152470 2021
31
Biomechanical Simulation of Peyronie's Disease. 61
33790989 2021
32
Is Kelami's Method Still Useful in the Smartphone Era? The Virtual 3-Dimensional Reconstruction of Penile Curvature in Patients With Peyronie's Disease: A Pilot Study. 61
33191184 2021
33
Long-term patient-reported outcomes in men with Peyronie's disease undergoing nonsurgical and nonintralesional injection management. 61
31988423 2021
34
Is Peyronie's an IgG4-related disease? 61
33545024 2021
35
Implications of Calcification in Peyronie's Disease, A Review of the Literature. 61
33476600 2021
36
Impact of treatment-related adverse events on efficacy of intralesional collagenase therapy for Peyronie's disease. 61
32457499 2021
37
Efficacy and safety of collagenase Clostridium histolyticum in Peyronie's disease following a modified treatment protocol. 61
33531284 2021
38
Human Penile Ossification: A Rare Cause of Sexual Dysfunction - A Case Report and Review of the Literature. 61
33489632 2021
39
Stretched penile length and its associations with testosterone and infertility. 61
33532295 2021
40
The Management of Penile Fracture: a Review of the Literature with Special Consideration for Patients Undergoing Collagenase Clostridium Histolyticum Injection Therapy. 61
33471204 2021
41
Peyronie's disease: new paradigm for the treatment of a unique cause of erectile dysfunction. 61
33156731 2020
42
Peyronie's Disease: What About the Female Sexual Partner? 61
33341426 2020
43
Conservative management of suspected fractures in men undergoing collagenase clostridium histolyticum for Peyronie's Disease is not associated with worsening of erectile function. 61
33318638 2020
44
Penile curvature after Peyronie's disease surgery: What are the risk factors? 61
33141941 2020
45
Re: The Surgical Treatment of Peyronie's Disease in the Older Man: Patient Characteristics and Surgical Outcomes in Men 65 and Older. 61
32960700 2020
46
Long-term Curvature Deformity Characterization in Men Previously Treated With Collagenase Clostridium Histolyticum for Peyronie's Disease, Subgrouped by Penile Plaque Calcification. 61
32896582 2020
47
[Biotherapies for erectile dysfunction and Peyronie's disease: Where are we now?] 61
32826194 2020
48
Treatment Trends and Cost Associated With Peyronie's Disease. 61
33036960 2020
49
Salvage Penile Plication Is an Effective Modality for Resolving Residual Curvature After Surgery for Peyronie's Disease. 61
33036958 2020
50
A Population-Based Study of Peyronie's Disease in Turkey: Prevalence and Related Comorbidities. 61
33243422 2020

Variations for Peyronie's Disease

Expression for Peyronie's Disease

Search GEO for disease gene expression data for Peyronie's Disease.

Pathways for Peyronie's Disease

Pathways related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 PTN
2
Show member pathways
13.68 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 MSTN
3
Show member pathways
13.55 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 PTN
4
Show member pathways
13.54 TGFB3 TGFB2 TGFB1 SMAD7 SMAD4 SMAD3
5
Show member pathways
13.34 TGFB1 IL6 IFNA2 IFNA1 HLA-A CCL2
6
Show member pathways
13.33 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 PTN
7
Show member pathways
13.27 WNT2 TGFB3 TGFB2 TGFB1 PTN IL6
8
Show member pathways
13.23 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 IL6
9
Show member pathways
13.07 TGFB3 TGFB2 TGFB1 PTN IL6 CCL2
10
Show member pathways
13.05 TGFB3 TGFB2 TGFB1 PTN IL6
11
Show member pathways
12.98 WNT2 IL6 IFNA2 IFNA1 HLA-A
12
Show member pathways
12.94 IL6 IFNA2 IFNA1 HLA-A CCL2
13
Show member pathways
12.88 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
14
Show member pathways
12.87 TGFB1 IL6 IFNA2 IFNA1 HLA-A
15
Show member pathways
12.84 IL6 IFNA2 IFNA1 HLA-A CCL2
16 12.83 IL6 IFNA2 IFNA1 HLA-A CCL2
17
Show member pathways
12.82 WNT2 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
18
Show member pathways
12.73 TGFB3 TGFB2 TGFB1 PTN IL6
19 12.7 WNT2 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
20
Show member pathways
12.64 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 IL6
21
Show member pathways
12.61 TGFB3 TGFB2 TGFB1 IL6
22
Show member pathways
12.53 WNT2 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
23 12.44 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
24
Show member pathways
12.42 TGFB3 TGFB2 TGFB1 PTN IL6
25 12.38 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 IL6
26
Show member pathways
12.35 WNT2 TGFB1 SMAD3 IL6
27 12.34 WNT2 TGFB2 TGFB1 DCN
28
Show member pathways
12.33 TGFB1 SMAD7 SMAD4 SMAD3
29 12.31 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
30 12.31 TGFB3 TGFB2 TGFB1 IL6 IFNA2 IFNA1
31
Show member pathways
12.29 TGFB3 TGFB2 TGFB1 IL6
32 12.28 IL6 IFNA2 IFNA1 CCL2
33
Show member pathways
12.26 TGFB2 TGFB1 SMAD4 SMAD3
34 12.24 TGFB3 TGFB2 TGFB1 SMAD3 IL6 HLA-A
35
Show member pathways
12.18 TGFB3 TGFB2 TGFB1 PTN IL6 IFNA2
36
Show member pathways
12.16 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 IL6
37 12.13 TGFB1 SMAD7 SMAD4 SMAD3
38 12.06 WNT2 TGFB1 IL6
39 12.06 TGFB1 SMAD3 IL6
40 12.06 WNT2 TGFB1 SMAD4 SMAD3
41 12.02 TGFB1 SMAD4 SMAD3 IL6
42 12.02 WNT2 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
43 12.01 TGFB1 IL6 CCL2
44 12 TGFB3 TGFB2 TGFB1 IL6
45 11.98 TGFB1 IL6 CCL2
46
Show member pathways
11.96 TGFB1 SMAD4 SMAD3 IL6
47 11.96 TGFB3 TGFB2 TGFB1 IL6 CCL2
48 11.94 TGFB3 TGFB2 TGFB1 CCL2
49 11.94 TGFB3 TGFB2 TGFB1 SMAD7 SMAD4 SMAD3
50 11.91 TGFB3 TGFB2 TGFB1 IL6 HLA-A DCN

GO Terms for Peyronie's Disease

Cellular components related to Peyronie's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.73 WNT2 TGFB3 TGFB2 TGFB1 IFNA2 DCN
2 extracellular region GO:0005576 9.7 WNT2 TGFB3 TGFB2 TGFB1 PTN MSTN
3 platelet alpha granule lumen GO:0031093 9.5 TGFB3 TGFB2 TGFB1
4 SMAD protein complex GO:0071141 9.37 SMAD4 SMAD3
5 extracellular space GO:0005615 9.36 WNT2 TGFB3 TGFB2 TGFB1 PTN MSTN
6 heteromeric SMAD protein complex GO:0071144 9.33 SMAD7 SMAD4 SMAD3

Biological processes related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 WNT2 TGFB3 TGFB1 SMAD7 SMAD4 SMAD3
2 positive regulation of transcription, DNA-templated GO:0045893 10.17 TGFB3 TGFB1 SMAD4 SMAD3 MSTN IL6
3 positive regulation of cell proliferation GO:0008284 10.12 WNT2 TGFB3 TGFB2 TGFB1 PTN IL6
4 negative regulation of cell proliferation GO:0008285 10.11 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 IL6
5 cytokine-mediated signaling pathway GO:0019221 10.05 TGFB1 IL6 IFNA2 IFNA1 CCL2
6 positive regulation of apoptotic process GO:0043065 10.03 TGFB3 TGFB1 PTN IL6
7 response to hypoxia GO:0001666 10 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
8 regulation of cell proliferation GO:0042127 9.99 TGFB3 TGFB2 TGFB1 SMAD4
9 negative regulation of cell growth GO:0030308 9.97 TGFB2 TGFB1 SMAD4 SMAD3
10 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.94 TGFB3 TGFB1 SMAD7 SMAD3
11 cell cycle arrest GO:0007050 9.91 TGFB2 TGFB1 SMAD3
12 negative regulation of angiogenesis GO:0016525 9.9 TGFB2 PTN DCN
13 platelet degranulation GO:0002576 9.9 TGFB3 TGFB2 TGFB1
14 positive regulation of DNA-binding transcription factor activity GO:0051091 9.9 WNT2 SMAD3 IL6
15 cellular response to transforming growth factor beta stimulus GO:0071560 9.9 WNT2 TGFB1 SMAD7 SMAD3
16 humoral immune response GO:0006959 9.89 IL6 IFNA2 IFNA1 CCL2
17 cellular response to organic cyclic compound GO:0071407 9.88 TGFB1 PTN CCL2
18 type I interferon signaling pathway GO:0060337 9.88 IFNA2 IFNA1 HLA-A
19 negative regulation of epithelial cell proliferation GO:0050680 9.88 TGFB2 TGFB1 PTN
20 positive regulation of cell division GO:0051781 9.88 TGFB3 TGFB2 TGFB1 PTN
21 wound healing GO:0042060 9.88 TGFB3 TGFB2 TGFB1 SMAD3 DCN
22 inner ear development GO:0048839 9.87 TGFB3 TGFB2 TGFB1
23 negative regulation of fat cell differentiation GO:0045599 9.86 TGFB1 SMAD3 IL6
24 positive regulation of protein secretion GO:0050714 9.86 TGFB3 TGFB2 TGFB1
25 response to progesterone GO:0032570 9.86 TGFB3 TGFB2 TGFB1 PTN
26 extrinsic apoptotic signaling pathway GO:0097191 9.85 TGFB2 TGFB1 SMAD3
27 ureteric bud development GO:0001657 9.85 TGFB1 SMAD7 SMAD3
28 ventricular septum morphogenesis GO:0060412 9.85 TGFB2 SMAD7 SMAD4
29 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.84 TGFB2 TGFB1 SMAD4 SMAD3
30 endoderm development GO:0007492 9.83 TGFB1 SMAD4 SMAD3
31 positive regulation of bone mineralization GO:0030501 9.83 TGFB3 TGFB1 SMAD3 PTN
32 positive regulation of SMAD protein signal transduction GO:0060391 9.81 TGFB3 TGFB1 SMAD4
33 secondary palate development GO:0062009 9.8 TGFB3 TGFB2 SMAD4
34 pathway-restricted SMAD protein phosphorylation GO:0060389 9.79 TGFB2 TGFB1 SMAD7
35 response to laminar fluid shear stress GO:0034616 9.75 TGFB3 TGFB1 SMAD7
36 salivary gland morphogenesis GO:0007435 9.74 TGFB3 TGFB2 TGFB1
37 interleukin-6-mediated signaling pathway GO:0070102 9.73 SMAD4 IL6
38 natural killer cell activation involved in immune response GO:0002323 9.73 IFNA2 IFNA1
39 positive regulation of interleukin-17 production GO:0032740 9.73 TGFB1 IL6
40 BMP signaling pathway GO:0030509 9.73 TGFB3 TGFB2 TGFB1 SMAD7 SMAD4 SMAD3
41 positive regulation of ossification GO:0045778 9.72 TGFB2 PTN
42 uterus development GO:0060065 9.72 TGFB2 SMAD4
43 positive regulation of leukocyte chemotaxis GO:0002690 9.72 PTN IL6
44 SMAD protein complex assembly GO:0007183 9.72 TGFB1 SMAD4 SMAD3
45 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.72 TGFB3 TGFB2 TGFB1 SMAD4 MSTN
46 cardiac epithelial to mesenchymal transition GO:0060317 9.71 WNT2 TGFB2
47 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.71 TGFB1 IL6
48 lens fiber cell differentiation GO:0070306 9.71 TGFB1 SMAD3
49 cell-cell junction organization GO:0045216 9.71 TGFB3 TGFB2 TGFB1 SMAD3
50 negative regulation of neuroblast proliferation GO:0007406 9.7 TGFB1 PTN

Molecular functions related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.37 WNT2 TGFB3 TGFB2 TGFB1 SMAD7 SMAD4
2 signaling receptor binding GO:0005102 9.85 WNT2 TGFB2 MSTN HLA-A CCL2
3 collagen binding GO:0005518 9.71 SMAD7 SMAD4 SMAD3 DCN
4 growth factor activity GO:0008083 9.63 TGFB3 TGFB2 TGFB1 PTN MSTN IL6
5 I-SMAD binding GO:0070411 9.61 SMAD7 SMAD4 SMAD3
6 type I transforming growth factor beta receptor binding GO:0034713 9.54 TGFB3 TGFB1 SMAD7
7 type II transforming growth factor beta receptor binding GO:0005114 9.5 TGFB3 TGFB2 TGFB1
8 type I interferon receptor binding GO:0005132 9.48 IFNA2 IFNA1
9 type III transforming growth factor beta receptor binding GO:0034714 9.43 TGFB3 TGFB2 TGFB1
10 cytokine activity GO:0005125 9.28 WNT2 TGFB3 TGFB2 TGFB1 MSTN IL6
11 transforming growth factor beta receptor binding GO:0005160 9.26 TGFB3 TGFB2 TGFB1 SMAD3

Sources for Peyronie's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....